Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function.

Neuron | 2015

The mechanisms by which mutations in FUS and other RNA binding proteins cause ALS and FTD remain controversial. We propose a model in which low-complexity (LC) domains of FUS drive its physiologically reversible assembly into membrane-free, liquid droplet and hydrogel-like structures. ALS/FTD mutations in LC or non-LC domains induce further phase transition into poorly soluble fibrillar hydrogels distinct from conventional amyloids. These assemblies are necessary and sufficient for neurotoxicity in a C. elegans model of FUS-dependent neurodegeneration. They trap other ribonucleoprotein (RNP) granule components and disrupt RNP granule function. One consequence is impairment of new protein synthesis by cytoplasmic RNP granules in axon terminals, where RNP granules regulate local RNA metabolism and translation. Nuclear FUS granules may be similarly affected. Inhibiting formation of these fibrillar hydrogel assemblies mitigates neurotoxicity and suggests a potential therapeutic strategy that may also be applicable to ALS/FTD associated with mutations in other RNA binding proteins.

Pubmed ID: 26526393 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: Medical Research Council, United Kingdom
    Id: MR/K02292X/1
  • Agency: European Research Council, International
    Id: 322817
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS07377
  • Agency: Wellcome Trust, United Kingdom
    Id: 089703
  • Agency: Medical Research Council, United Kingdom
    Id: MC_G1000734
  • Agency: CIHR, Canada
  • Agency: Arthritis Research UK, United Kingdom
  • Agency: Wellcome Trust, United Kingdom
    Id: 084812
  • Agency: Medical Research Council, United Kingdom
    Id: G0902243
  • Agency: Wellcome Trust, United Kingdom
    Id: 100140
  • Agency: Wellcome Trust, United Kingdom
    Id: 081864

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


SigmaPlot (tool)

RRID:SCR_003210

Statistical analysis and scientific graphing software for Windows OS.

View all literature mentions

SH-SY5Y (tool)

RRID:CVCL_0019

Cell line SH-SY5Y is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions